Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis

Clinical Infectious Diseases

Volumn 59, Issue 4, 2014, Pages 493-500

  Jarvis, Joseph N ^a,b,c   Bicanic, Tihana ^d   Loyse, Angela ^d   Meintjes, Graeme ^e,f   Hogan, Louise ^d   Roberts, Chrissy H ^a   Shoham, Shmuel ^g   Perfect, John R ^h   Govender, Nelesh P ⁱ   Harrison, Thomas S ^d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b BOTSWANA UPENN PARTNERSHIP   (Botswana)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

Cryptococcal meningitis; HIV; South Africa; Tuberculosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CD14 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 6; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA; 25-HYDROXYVITAMIN D; CYTOKINE; VITAMIN D;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID CULTURE; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; FUNGICIDAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PATHOGEN CLEARANCE; PRIORITY JOURNAL; SEASONAL VARIATION; SOUTH AFRICA; TUBERCULOSIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; BACTERIAL COUNT; BLOOD; CEREBROSPINAL FLUID; COMPLICATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MENINGITIS, CRYPTOCOCCAL; PATHOLOGY; SEASON; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD14; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS NEOFORMANS; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; NEOPTERIN; SEASONS; SOUTH AFRICA; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84904973793     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu349     Document Type: Article

References (42)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-30.
2. Coelho C, Bocca A, Casadevall A. The intracellular life of Cryptococcus neoformans. Annu Rev Pathol 2014; 9: 219-38.
3. Johnston SA, May RC. Cryptococcus interactions with macrophages: evasion and manipulation of the phagosome by a fungal pathogen. Cell Microbiol 2013; 15: 403-11.
4. Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001; 107:E66.
5. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007; 21: 2119-29.
6. Jarvis JN, Dromer F, Harrison TS, Lortholary O. Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis 2008; 21: 596-603.
7. Davis MJ, Tsang TM, Qiu Y, et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio 2013; 4:e00264-13.
8. Anandaiah A, Sinha S, Bole M, et al. Vitamin D rescues impaired Mycobacterium tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-seropositive individuals through an enhanced Toll-like receptor signaling pathway in vitro. Infect Immun 2013; 81: 2-10.
9. Campbell GR, Spector SA. Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 2012; 8: e1002689.
10. Coussens AK, Wilkinson RJ, Hanifa Y, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 2012; 109: 15449-54.
11. Fabri M, Stenger S, Shin DM, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011; 3: 104ra2.
12. Realegeno S, Modlin RL. Shedding light on the vitamin D-tuberculosis-HIV connection. Proc Natl Acad Sci U S A 2011; 108: 18861-2.
13. Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc 2012; 71: 50-61.
14. Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 2011; 108: 19013-7.
15. Lawn SD, Wood R. Incidence of tuberculosis during highly active anti-retroviral therapy in high-income and low-income countries. Clin Infect Dis 2005; 41: 1783-6.
16. Jarvis JN, Harrison TS, Corbett EL, Wood R, Lawn SD. Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease? AIDS 2009; 24: 612-4.
17. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47: 123-30.
18. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26: 1105-13.
19. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764-7.
20. Siddiqui AA, Brouwer AE, Wuthiekanun V, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005; 174: 1746-50.
21. Holick MF Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
22. Barnett AG, Dobson AJ. Analysing seasonal health data (statistics for biology and health). Berlin Heidelberg: Springer, 2010.
23. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014; 58: 736-45.
24. Thompson GR III, Bays D, Taylor SL, Cohen SH, Pappagianis D. Association between serum 25-hydroxyvitamin D level and type of coccidioidal infection. Med Mycol 2013; 51: 319-23.
25. Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responsesto Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010; 120: 3242-54.
26. Conesa-Botella A, Meintjes G, Coussens AK, et al. Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. Clin Infect Dis 2012; 55: 1004-11.
27. Sudfeld CR, Giovannucci EL, Isanaka S, et al. Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected Tanzanian adults initiating antiretroviral therapy. J Infect Dis 2013; 207: 378-85.
28. Mastala Y, Nyangulu P, Banda RV, Mhemedi B, White SA, Allain TJ. Vitamin D deficiency in medical patients at a central hospital in Malawi: a comparison with TB patients from a previous study. PLoS One 2013; 8:e59017.
29. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D (3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-50.
30. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D. 1,25-dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 1998; 66: 5314-21.
31. Sly LM, Lopez M, Nauseef WM, Reiner NE. 1alpha,25-dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J Biol Chem 2001; 276: 35482-93.
32. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179: 2060-3.
33. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119: 753-66.
34. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006; 313: 1438-41.
35. Hardison SE, Herrera G, Young ML, Hole CR, Wozniak KL, Wormley FL. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J Immunol 2012; 189: 4060-8.
36. Wozniak KL, Hardison S, Olszewski M, Wormley FL. Induction of protective immunity against cryptococcosis. Mycopathologia 2012; 173: 387-94.
37. Jarvis JN, Casazza JP, Stone HH, et al. The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis 2013; 207: 1817-28.
38. Khoo AL, Chai LY, Koenen HJ, et al. Vitamin D(3) down-regulates proinflammatory cytokine response to Mycobacterium tuberculosis through pattern recognition receptors while inducing protective cathelicidin production. Cytokine 2011; 55: 294-300.
39. Selvaraj P, Harishankar M, Singh B, Banurekha VV, Jawahar MS. Effect of vitamin D3 on chemokine expression in pulmonary tuberculosis. Cytokine 2012; 60: 212-9.
40. Martineau AR Vitamin D: an adjunct to antiretroviral therapy? J Infect Dis 2013; 207: 373-5.
41. Loyse A, Wainwright H, Jarvis JN, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS 2009; 24: 405-10.
42. Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49: 702-9.